Taking Stock
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Haemocell, the blood products company which has been under intense pressure and was forced to mount a pounds 2m rescue rights issue, held at 4.5p. The chief executive, Brian Long, has displayed faith in the group's revival by buying 1 million shares, lifting his interest to nearly 4 per cent. At one time Haemocell seemed to be one of the more exciting health ventures. Its blood filter won US approval but problems over distributors retarded its progress. The group has switched to its own selling force, a move which is thought to be paying off.
Malaya, the luxury car group embracing HR Owen, continues to attract Singapore multi-millionaire Ong Beng Seng. His interests picked up another 500,000 shares and now account for 25.28 per cent; the price is 12.5p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments